Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on October 12, 2016, regarding an event that occurred on September 7, 2016. The Company is incorporated in Nevada and is headquartered in Cranford, NJ.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or overall liquidity metrics. The primary financial disclosure concerns a new debt obligation:
- New Debt Principal: $500,000
- Interest Rate: Prime Rate (as published in the Wall Street Journal on the last day of the month) plus 1%
- Maturity Date: The earlier of December 31, 2016, or upon demand by the Lender
- Lender Identity: Leonard Mazur, Executive Chairman, Secretary, and Director of the Company
Material Changes
The Company entered into a Material Definitive Agreement (Item 1.01) and created a Direct Financial Obligation (Item 2.03) by executing a demand promissory note. This represents a new liability on the balance sheet not present in prior periods.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the immediate obligation to repay the note. The note is a demand instrument, creating a liquidity risk as the lender may require repayment at any time prior to the December 31, 2016 maturity date.
Investor Verification Checklist
- Verify the Company's current cash position to assess ability to repay the $500,000 demand note if called immediately.
- Confirm the current "Prime Rate" to calculate the exact interest expense.
- Review the full text of the Demand Promissory Note (Exhibit 10.1) for any covenants or default provisions not summarized in the 8-K.
- Assess the impact of this related-party transaction on the Company's overall debt-to-equity ratio.